# David Evans

> David Evans is a Series C investor in Sydney backing Genetics and Biopharma. See 2 investments, round sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Location: Sydney, Australia
- Total investments: 2
- Last investment: Jun 2013
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: http://au.linkedin.com/in/davidevans6591

David Evans is a Series C investor in Sydney focused on Genetics and Biopharma. David is the inventor/product designer and owner of Tyson and has an extensive background in the locking solutions market with over 20 years experience from product conceptualization, design and development, engineering, quality control, manufacturing and sales and marketing. He has worked with international firms including ASSA ABLOY,D&D Technologies that has resulted in the design, manufacture and distribution of a range of locking products. David has personally managed and negotiated manufacturing contracts in China and been instrumental in the establishment of new distribution agreements for these products in Australia.

## Contacts

5 contacts available for David Evans: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/david-evans-10?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Genetics | 1 | 50% |
| Biopharma | 1 | 50% |
| Biotechnology | 1 | 50% |
| Health Diagnostics | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 1 | 50% |
| Funding Round | 1 | 50% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Horizon Discovery | Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company’s gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated acatalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12, 000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline. | $8.8M |  | Jun 03, 2013 | http://www.horizondiscovery.com |
| Horizon Discovery | Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company’s gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated acatalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12, 000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline. | $14.4M | Series C | Sep 13, 2011 | http://www.horizondiscovery.com |

2 of 2 investments shown.

## Co-investors
- [Molten Ventures](https://shizune.co/investors/profile/draper-esprit) — VC Fund, 2 deals together
- [MVM Life Science Partners](https://shizune.co/investors/profile/mvm-life-science-partners) — VC Fund, 2 deals together
- [Roche Venture Fund](https://shizune.co/investors/profile/roche-venture-fund) — VC Fund, 2 deals together
- [Calculus Capital](https://shizune.co/investors/profile/calculus-capital) — VC Fund, 1 deal together
- [Parkwalk Advisors](https://shizune.co/investors/profile/parkwalk-advisors) — VC Fund, 1 deal together
- [Providence Investment Company Limited](https://shizune.co/investors/profile/providence-investment-company-limited) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Biotech Angel Investors in United Kingdom](https://shizune.co/investors/biotech-angel-investors-united-kingdom)

## FAQ

### What does David Evans invest in?

David Evans invests primarily in Genetics, Biopharma and Biotechnology startups, most often at Series C and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact David Evans?

Public channels for David Evans include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did David Evans last invest?

The most recent investment recorded for David Evans closed in Jun 2013. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co